ARTICLE | Product Development
Takeda's deals paint a picture of a turnaround in action
A look at Takeda's deals shows the pharma is increasingly embracing edgier technologies
July 26, 2019 11:54 PM UTC
With a spate of new and expanded deals this year, Takeda is not letting its $62 billion dollar takeout of Shire slow its transformation from a traditional small molecule company to a home for edgier, riskier science, built on multiple modalities.
Since joining as COO in 2014, President and CEO Christophe Weber has been remaking Takeda from a segmented, small molecule-focused company into a pharma plugged into innovation in global hotspots (see “Taking Takeda Global”)...